News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Study Links Higher Vitamin D Levels to Improved Colorectal Ca Survival

Jul 1, 2008
Oncology NEWS InternationalOncology NEWS International Vol 17 No 7
Volume 17
Issue 7

Colon cancer patients who had abundant levels of vitamin D were less likely to die during a follow-up period than those who were deficient in the vitamin, according to a study by scientists at Dana-Farber Cancer Institute and the Harvard School of Public Health (J Clin Oncol 26:2984-2991, 2008).

ABSTRACT: Patients in the highest quartile of vitamin D levels had improved overall and cancer-specific survival, compared to the lowest quartile.

Colon cancer patients who had abundant levels of vitamin D were less likely to die during a follow-up period than those who were deficient in the vitamin, according to a study by scientists at Dana-Farber Cancer Institute and the Harvard School of Public Health (J Clin Oncol 26:2984-2991, 2008).

Previous research has shown that higher levels of vitamin D reduce the risk of developing colorectal cancer by about 50%, but the effect on outcomes wasn’t known.

The investigators, led by Kimmie Ng, MD, MPH, and Charles Fuchs, MD, MPH, of Dana-Farber, analyzed data from two long-running epidemiologic studies -the Nurses’ Health Study and the Health Professionals Follow-up Study.

They identified 304 participants who were diagnosed with colorectal cancer between 1991 and 2002. All had 25-hydroxyvitamin D3 plasma levels measured in samples given at least 2 years prior to their diagnosis. They were stratified into quartiles of vitamin D levels ranging from a mean of 16.5 ng/mL to 40 ng/mL.

Patients were followed until they died or until 2005, whichever occurred first. During that period, 123 patients died, 96 of them from colorectal cancer.

Study Results

The study showed that mortality fell as prediagnostic vitamin D levels rose (P = .02).

Individuals with vitamin D levels in the highest quartile were 48% less likely to die from any cause those with the lowest vitamin D levels. The odds of dying from colon cancer were 39% lower for the highest vs the lowest quartiles.

“Additional efforts to understand the mechanisms through which the vitamin D pathway influences colorectal carcinogenesis and cancer progression are warranted,” the authors concluded.

Dr. Ng noted that a trial is being planned in which colon cancer patients will take vitamin D supplements along with adjuvant chemotherapy to look for any benefits of the supplements. Meanwhile, Dr. Ng recommended that individuals with colon cancer consult their physician as to whether or not they should add vitamin supplements to their daily regimen.

Standard recommended daily amounts of vitamin D supplements range from 200 IU/d for people under age 50 to 400 IU for people between 50 and 70, and 600 IU for those over age 70.

Articles in this issue

National Cancer Survivors Day
New Indication for Velcade in Previously Untreated Myeloma
Risk Factors for Mantle Cell Lymphoma Identified
RAS Mutations Enhance Chemotherapy in AML
Antidiabetic Agent Metformin May Boost pCRs in Breast Ca
Eisai Seeks Full FDA Approval for Ontak for CTCL
Symptom Screen Plus CA125 Detects Early Ovarian Ca
Cisplatin Linked to Cardiac Complications in Testicular Ca Patients
Updated X-ACT Study Results Presented
ThromboGenics and BioInvent Announce Alliance with Roche
Gene Signature Identifies Low-Risk Patients in MAGE-A3 Trial
p110-Beta Drives Cancer Growth When PTEN is Inhibited, Animal Study Shows
Proton beam RT not exempt from evidence-based medicine
Investigational Agents May be Effective for Resistant GIST
Coverage vs Cost-Cutting: A look Inside the Obama and McCain Healthcare Plans
Related Videos
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma
Experts on multiple myeloma
Expert on MM
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Related Content

Zotatifin Combo Yields Responses in Pretreated ER+ Metastatic Breast Cancer

June 5th 2023

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

May 15th 2023

Neoadjuvant Nivolumab/Chemo Improves Outcomes Vs Chemo in Resectable NSCLC

June 4th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

Elacestrant Improves PFS Vs SOC in ER+/HER2– Advanced Breast Cancer

June 4th 2023

PD-1/TIGIT Bispecific Has Preliminary Activity in Previously Treated NSCLC

June 4th 2023

Zotatifin Combo Yields Responses in Pretreated ER+ Metastatic Breast Cancer

June 5th 2023

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

May 15th 2023

Neoadjuvant Nivolumab/Chemo Improves Outcomes Vs Chemo in Resectable NSCLC

June 4th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

Elacestrant Improves PFS Vs SOC in ER+/HER2– Advanced Breast Cancer

June 4th 2023

PD-1/TIGIT Bispecific Has Preliminary Activity in Previously Treated NSCLC

June 4th 2023

Zotatifin Combo Yields Responses in Pretreated ER+ Metastatic Breast Cancer

June 5th 2023

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

May 15th 2023

Neoadjuvant Nivolumab/Chemo Improves Outcomes Vs Chemo in Resectable NSCLC

June 4th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

Elacestrant Improves PFS Vs SOC in ER+/HER2– Advanced Breast Cancer

June 4th 2023

PD-1/TIGIT Bispecific Has Preliminary Activity in Previously Treated NSCLC

June 4th 2023
Related Content

Zotaifin plus abemaciclib and fulvestrant appears to produce no dose-limiting toxicities among patients with estrogen receptor–positive metastatic breast cancer in a phase 1/2 study.

Zotatifin Combo Yields Responses in Pretreated ER+ Metastatic Breast Cancer

June 5th 2023
Article

Zotaifin plus abemaciclib and fulvestrant appears to produce no dose-limiting toxicities among patients with estrogen receptor–positive metastatic breast cancer in a phase 1/2 study.


Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.


Patients who receive nivolumab plus chemotherapy for non–small cell lung cancer may experience sustained improvement in time to death or distant metastasis, according to an expert from McGill University Health Center.

Neoadjuvant Nivolumab/Chemo Improves Outcomes Vs Chemo in Resectable NSCLC

June 4th 2023
Article

Patients who receive nivolumab plus chemotherapy for non–small cell lung cancer may experience sustained improvement in time to death or distant metastasis, according to an expert from McGill University Health Center.


Rakhshanda Rahman, MD, FRCS, FACS, emphasizes educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023
Podcast

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.


Elacestrant also appears to produce a manageable safety profile in the treatment of patients with estrogen receptor–positive HER2-negative advanced breast cancer in the phase 3 EMERALD trial.

Elacestrant Improves PFS Vs SOC in ER+/HER2– Advanced Breast Cancer

June 4th 2023
Article

Elacestrant also appears to produce a manageable safety profile in the treatment of patients with estrogen receptor–positive HER2-negative advanced breast cancer in the phase 3 EMERALD trial.


Rilvegostomig appears to yield no dose-limiting toxicities among patients with advanced or metastatic PD-L1–positive non–small cell lung cancer in the phase 1/2 ARTEMIDE-01 study.

PD-1/TIGIT Bispecific Has Preliminary Activity in Previously Treated NSCLC

June 4th 2023
Article

Rilvegostomig appears to yield no dose-limiting toxicities among patients with advanced or metastatic PD-L1–positive non–small cell lung cancer in the phase 1/2 ARTEMIDE-01 study.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.